Literature DB >> 33560092

Interest, Concerns, and Attitudes Among Men Who Have Sex With Men and Health Care Providers Toward Prophylactic Use of Doxycycline Against Chlamydia trachomatis Infections and Syphilis.

Justin J Park1, Chrysovalantis Stafylis1, Daniel D Pearce, Jeff Taylor2, Susan J Little3, Noah Kojima1, Aleksandr M Gorin1, Jeffrey D Klausner4.   

Abstract

BACKGROUND: Prophylactic administration of doxycycline is regarded as a potential new public health strategy to combat the rising rates of Chlamydia trachomatis infections and syphilis among men who have sex with men. We conducted a survey-based study to evaluate how community members and health care providers in Southern California would perceive doxycycline preexposure/postexposure prophylaxis (PrEP/PEP) to predict its acceptability and identify potential areas of concern.
METHODS: We conducted an online cross-sectional survey among community members who identify as men who have sex with men and health care providers with prescribing authority in Southern California to investigate the current attitudes toward doxycycline PrEP/PEP, including their willingness to accept. We analyzed the data using descriptive statistics and binary logistic regression.
RESULTS: Among 212 enrolled community member participants, 67.5% indicated they would take doxycycline PrEP/PEP if offered by their provider. Higher acceptability was significantly associated with several characteristics, including recent history of bacterial sexually transmitted infection diagnosis and current use of HIV PrEP. For health care providers, 89.5% of 76 enrolled participants expressed willingness to prescribe doxycycline PrEP/PEP to their patients if recommended by the Centers for Disease Control and Prevention, but only 43.4% were willing if not. Both community members and health care providers demonstrated high levels of concern toward possible drug resistance.
CONCLUSIONS: Doxycycline PrEP/PEP as a preventive strategy against chlamydial infections and syphilis would likely be accepted among community members and health care providers. Clear guidelines from public health officials and further clarification on the strategy's potential impact on developing drug resistance may be necessary to ensure successful implementation.
Copyright © 2021 American Sexually Transmitted Diseases Association. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33560092      PMCID: PMC8521638          DOI: 10.1097/OLQ.0000000000001395

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   3.868


  20 in total

1.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

2.  Changes in Sexual Behavior and STI Diagnoses Among MSM Initiating PrEP in a Clinic Setting.

Authors:  Michalina A Montaño; Julia C Dombrowski; Sayan Dasgupta; Matthew R Golden; Ann Duerr; Lisa E Manhart; Lindley A Barbee; Christine M Khosropour
Journal:  AIDS Behav       Date:  2019-02

3.  Chemoprophylaxis is likely to be acceptable and could mitigate syphilis epidemics among populations of gay men.

Authors:  David P Wilson; Garrett P Prestage; Richard T Gray; Alexander Hoare; Pol McCann; Ian Down; Rebecca J Guy; Fraser Drummond; Jeffrey D Klausner; Basil Donovan; John M Kaldor
Journal:  Sex Transm Dis       Date:  2011-07       Impact factor: 2.830

4.  Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections: Promises and Perils.

Authors:  Martin Siguier; Jean-Michel Molina
Journal:  ACS Infect Dis       Date:  2018-03-23       Impact factor: 5.084

5.  Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

Authors:  Jean-Michel Molina; Isabelle Charreau; Christian Chidiac; Gilles Pialoux; Eric Cua; Constance Delaugerre; Catherine Capitant; Daniela Rojas-Castro; Julien Fonsart; Béatrice Bercot; Cécile Bébéar; Laurent Cotte; Olivier Robineau; François Raffi; Pierre Charbonneau; Alexandre Aslan; Julie Chas; Laurence Niedbalski; Bruno Spire; Luis Sagaon-Teyssier; Diane Carette; Soizic Le Mestre; Veronique Doré; Laurence Meyer
Journal:  Lancet Infect Dis       Date:  2017-12-08       Impact factor: 25.071

6.  Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis.

Authors:  Michael W Traeger; Sophia E Schroeder; Edwina J Wright; Margaret E Hellard; Vincent J Cornelisse; Joseph S Doyle; Mark A Stoové
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

7.  High Interest in Doxycycline for Sexually Transmitted Infection Postexposure Prophylaxis in a Multicity Survey of Men Who Have Sex With Men Using a Social Networking Application.

Authors:  Matthew A Spinelli; Hyman M Scott; Eric Vittinghoff; Albert Y Liu; Kenneth Coleman; Susan P Buchbinder
Journal:  Sex Transm Dis       Date:  2019-04       Impact factor: 2.830

Review 8.  Global challenge of antibiotic-resistant Treponema pallidum.

Authors:  Lola V Stamm
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

9.  Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection - A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis.

Authors:  Ricardo Niklas Werner; Matthew Gaskins; Alexander Nast; Corinna Dressler
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

Review 10.  Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections.

Authors:  Juliana S Grant; Chrysovalantis Stafylis; Connie Celum; Troy Grennan; Bridget Haire; John Kaldor; Anne F Luetkemeyer; John M Saunders; Jean-Michel Molina; Jeffrey D Klausner
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

View more
  4 in total

1.  BASHH updated position statement on doxycycline as prophylaxis for sexually transmitted infections.

Authors:  Manik Kohli; Nicholas Medland; Helen Fifer; John Saunders
Journal:  Sex Transm Infect       Date:  2022-05       Impact factor: 4.199

2.  Nanoparticle-Based Lateral Flow Biosensor Integrated With Loop-Mediated Isothermal Amplification for Rapid and Visual Identification of Chlamydia trachomatis for Point-of-Care Use.

Authors:  Xu Chen; Qingxue Zhou; Yan Tan; Ronghua Wang; Xueli Wu; Jiangli Liu; Rui Liu; Shuoshi Wang; Shilei Dong
Journal:  Front Microbiol       Date:  2022-07-12       Impact factor: 6.064

3.  Awareness and willingness to accept syphilis chemoprophylaxis among men who have sex with men from three cities in China: a cross-sectional study.

Authors:  Xu Zhang; Shu-Zhen Qi; Fang-Zhi Du; Zhi-Ju Zheng; Ning-Xiao Cao; Xiao-Li Zheng; Rui-Li Zhang; Qian-Qiu Wang
Journal:  BMC Public Health       Date:  2022-10-15       Impact factor: 4.135

4.  Doxycycline for Sexually Transmitted Infection Prevention: Evolving Evidence and Implementation Perspectives.

Authors:  Connie Celum; Anne F Luetkemeyer
Journal:  Sex Transm Dis       Date:  2021-09-01       Impact factor: 2.830

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.